显微手术治疗丘脑胶质瘤患者的生存状况研究

Survival Conditions of Thalamic Glioma Patients with Microsurgery Treatment

[目的]探讨显微手术治疗的丘脑胶质瘤患者的生存状况。[方法]选取2005年8月至2015年12月在西安交通大学第一附属医院神经外科通过显微外科手术进行治疗的丘脑胶质瘤患者80例为观察组；其中单纯显微手术治疗32例，显微手术后辅助放化疗48例。选取同期传统手术治疗丘脑胶质瘤患者80例为对照组。分析观察组患者的总体生存率（OS）和无疾病进展生存率（PFS）、术后随访情况和两组患者手术后的并发症发生情况。[结果]经过多因素分析显示，观察组术后1年OS、PFS的预后影响因素是病理类型和治疗方法（均P〈0．05）。3个月、6个月和12个月观察组OS分别为96％、90％和70％，PFS分别为90％、80％和60％。观察组并发症的发生率为55．0％（44／80）显著低于对照组的90．0％（72／80），差异具有统计学意义（P〈0．01）。[结论]对丘脑胶质瘤患者进行显微外科手术治疗可以有效改善丘脑胶质瘤患者的预后，降低了患者术后并发症的发生率，加快了患者的康复进程。

[Objective]To investigate the survival conditions of thalamic glioma patients after microsurgery treatment.[Methods]Eighty thalamic glioma patients treated by microsurgical operation were selected from August 2005 to December 2015 as study group in the Neurosurgery Department of our hospital. 32 cases of them received microsurgical operation only and 48 cases were treated by microsurgical operation plus chemo radiotherapy. Furthermore, 80 thalamic glioma patients underwent traditional surgery were selected as control group. Patients＇ overall survival rate （OS）, disease free survival rate （PFS）, postoperative follow-up status and complications after surgery were observed. [Results]Multiple factor analysis showed that the prognostic factors of OS and PFS of the observation group 1 year after surgery were of pathological type and treatment approach （mean P〈0.05）. OS of the observation group at 3 months, 6 months and 12 months were 96%, 90% and 70 %, respectively, and those of PFS were 90 %, 80 % and 60 %, respectively. The incidence of complications in the observation group was 55% （44/80）, significantly lower than that of the control group 90% （72/80）, the difference was statistically significant （ P 〈0.01）.[Conclusion]Microsurgical surgery for thalamic glioma patients can not only effectively improve patient prognosis, but also remedy for the deficiency of the traditional surgery, reduce the incidence of postoperative complications and accelerate the therapy-recovery process.